Marijuana Rehab Cost: When to Get Help, 28-Day Pricing, and CHS Treatment
Cannabis rehab costs $11,000 to $35,000 for a 30-day inpatient program without insurance, or $4,500 to $15,000 out-of-pocket with PPO insurance. Medical stabilization costs $800 to $2,500 for 3–7 days because cannabis withdrawal isn’t medically dangerous. Most cannabis use disorder is treated outpatient with CBT and motivational enhancement therapy — typically $3,000 to $8,000 self-pay or $1,000 to $3,000 insured for a 12-week course.
| Phase | Duration | Without Insurance | With PPO |
|---|---|---|---|
| Medical stabilization (optional) | 3–7 days | $800 – $2,500 | $450 – $1,925 |
| Inpatient residential | 30 days | $11,000 – $35,000 | $4,500 – $15,000 |
| Inpatient residential | 60 days | $22,000 – $70,000 | $8,000 – $30,000 |
| PHP | 4–6 weeks | $6,000 – $20,000 | Capped at OOP max |
| IOP (primary modality for most) | 8–12 weeks | $3,000 – $8,000 | $1,000 – $3,000 |
| Standard outpatient (weekly) | Ongoing | $400 – $800/month | $120 – $300 |
Cannabis use disorder affects approximately 4 million Americans per NIDA. The rise of high-THC concentrates (80–99% THC vs 4% THC in 1995) has substantially increased dependence, withdrawal, and Cannabinoid Hyperemesis Syndrome (CHS) presentations. Most cannabis use disorder is treated outpatient — inpatient is reserved for severe cases with co-occurring conditions. This guide answers the four most-searched cost questions and covers the 2020–2026 developments (high-THC concentrates, CHS, delta-8/delta-9/delta-10 products) that most cannabis rehab cost pages skip.
How Much Does a Marijuana Addiction Cost?
The cost of untreated cannabis use disorder — purchases plus lost productivity plus medical plus legal — is rarely calculated. For a daily heavy user:
| Category | Annual Range |
|---|---|
| Cannabis purchases ($8–$40/day) | $3,000 – $15,000 |
| Productivity loss (impaired work, reduced earnings) | $5,000 – $25,000 |
| Cannabinoid Hyperemesis Syndrome ER visits | $1,500 – $15,000+ |
| DUI legal costs (if applicable) | $10,000 – $25,000 |
| Mental health care worsened by use | $2,000 – $10,000 |
| Conservative annual total | $21,500 – $90,000 |
This frames the treatment-vs-no-treatment decision. A 30-day inpatient at $4,500–$15,000 insured OOP or a 12-week IOP with CBT at $1,000–$3,000 insured is usually far less than one year of untreated moderate-to-severe cannabis use disorder plus associated costs.
Should You Go to Rehab for Marijuana?
Yes, if you meet criteria for cannabis use disorder and have tried unsuccessfully to quit. Not every person who uses cannabis needs treatment — rehab is warranted when specific clinical criteria apply.
Clinical Criteria (DSM-5 Cannabis Use Disorder)
2–3 of the following = mild; 4–5 = moderate; 6+ = severe. Over 12 months:
- Using more or longer than intended
- Unsuccessful efforts to cut down or quit
- Significant time spent obtaining, using, or recovering from cannabis
- Cravings
- Use that interferes with work, school, or home obligations
- Continued use despite social or interpersonal problems
- Giving up important activities because of use
- Use in physically hazardous situations (e.g., driving)
- Continued use despite knowing it’s causing a physical or psychological problem
- Tolerance (needing more for the same effect)
- Withdrawal symptoms when not using
Other Strong Indicators
- Daily use of high-THC concentrates (wax, shatter, live resin) — significantly higher dependence risk than flower
- History of Cannabinoid Hyperemesis Syndrome (CHS) — recurrent vomiting resolved only by cessation
- Co-occurring depression or anxiety worsened by use
- Adolescent or young-adult use with academic/occupational decline
- Legal consequences (possession, DUI, custody disputes)
- Relationship or family consequences
What Level of Care?
- Inpatient (30 days): Severe use disorder + co-occurring psychiatric conditions, unsafe living environment, prior outpatient failures
- PHP (2–4 weeks): Transitioning from inpatient, or moderate-severe with stable housing
- IOP (12 weeks): Primary level for most cannabis use disorder — CBT + motivational enhancement + contingency management
- Standard outpatient: Mild-to-moderate use, strong support system
Most cannabis use disorder is adequately treated at the IOP level or below. See types of rehab programs.
How Much Is 28 Days of Marijuana Rehab?
Standard insurance billing cycle.
- Self-pay: $10,000 – $33,000
- PPO out-of-pocket: $4,000 – $14,000 — typically capped at $7,000–$9,500 OOP max
Cannabis rehab is usually the cheapest rehab of any substance because:
- No medically dangerous withdrawal requiring intensive detox
- No MAT medication costs (none are FDA-approved for cannabis)
- Lower acuity means some patients don’t need inpatient at all
Worked Example
Facility bills $28,000 for 28 days. Plan: $2,000 deductible / 20% coinsurance / $8,000 OOP max.
- Deductible: $2,000
- 20% of $26,000: $5,200
- Running total: $7,200 — below OOP max cap, so that’s what you pay
Do You Have to Pay for Marijuana Rehab?
Rarely at full price. Payment sources:
| Source | Typical OOP |
|---|---|
| PPO insurance | $4,500 – $18,000 (capped at OOP max) |
| HMO | $3,500 – $14,000 |
| Medicaid | $0 – $100 |
| Medicare | Varies |
| Self-pay with financing | Sliding scale, scholarships, payment plans |
| EAP | Short-term coverage |
| State-funded | Free or income-indexed |
See does insurance cover rehab for full framework.
High-THC Concentrates: What Changed
Cannabis potency has fundamentally changed over the past 30 years.
| Product | Typical THC | Use Pattern |
|---|---|---|
| 1995 flower | 4% | Occasional |
| 2020 dispensary flower | 15–25% | Regular |
| 2024 concentrates (wax, shatter, live resin, rosin) | 80–99% | Frequent; highly dependence-forming |
| Delta-8 THC | Variable | Loophole product in non-legal states |
| Delta-9 hemp-derived | Variable | Loophole under 2018 Farm Bill |
| Delta-10 THC | Variable | Less common, similar to delta-8 |
Clinical Implications
- Higher dependence rates than historical cannabis
- CHS emergence increasingly linked to concentrate use
- Sharper withdrawal — more intense symptoms, longer duration
- Cognitive impact in adolescent and young-adult users
- Tolerance develops faster, requiring dose escalation
Treatment approaches are the same as traditional cannabis (CBT, MET, CM), but clinicians now routinely assess for concentrate use specifically because withdrawal severity and treatment duration often differ.
Cannabinoid Hyperemesis Syndrome (CHS): Growing Medical Cost
CHS is a clinical syndrome marked by recurrent severe nausea, vomiting, and abdominal pain in heavy cannabis users. First described in 2004; diagnoses have accelerated dramatically since 2015, particularly among concentrate users.
Clinical Features
- Episodes of severe vomiting lasting hours to days
- Severe abdominal pain
- Weight loss, dehydration
- Paradoxical relief from hot showers/baths (pathognomonic)
- Often misdiagnosed as gastroenteritis or cyclic vomiting syndrome before correct diagnosis
Cost
| Service | Typical Cost |
|---|---|
| ED visit for acute episode | $1,500 – $4,500 |
| Hospital admission (severe episodes) | $5,000 – $20,000 |
| Recurrent episodes (prior to diagnosis) | Often multiple ED visits |
| Capsaicin, haloperidol, IV fluids | Part of ED/hospital billing |
| Only reliable cure: Complete cannabis cessation | Treatment cost |
Insurance: CHS is treated as a medical condition (not SUD), covered under inpatient hospital benefit. Accurate diagnosis often requires the clinician to ask specifically about cannabis use patterns.
CHS + Treatment Cost Implications
For CHS patients, inpatient cannabis rehab is often clinically indicated because it removes access to the substance during the symptom-resolution window (1–3 weeks). Insurance authorization for inpatient cannabis rehab is generally stronger when CHS is the presenting complication.
Cannabis Withdrawal Timeline
| Phase | Timeline | Typical Symptoms |
|---|---|---|
| Onset | Days 1–2 | Irritability, anxiety, decreased appetite |
| Peak | Days 2–6 | Severe sleep disruption, cravings, mood instability, restlessness |
| Resolution | Days 7–14 | Gradual symptom improvement |
| Protracted | 1–3 months | Intermittent sleep disruption, subtle cognitive effects (heavy users) |
Sleep normalizes last. Short-term non-addictive sleep aids (trazodone, melatonin, hydroxyzine) during the first 2–3 weeks often help.
Treatment Modalities for Cannabis Use Disorder
No FDA-approved medications. Behavioral therapy does the clinical work.
Primary Evidence-Based Approaches
- Cognitive Behavioral Therapy (CBT) — identifying and changing cannabis-related thought patterns and behaviors
- Motivational Enhancement Therapy (MET) — resolving ambivalence about change
- Contingency Management (CM) — rewards for verified abstinence (strong evidence for cannabis)
- Family therapy — especially for adolescents and young adults
- Group therapy — 12-step, SMART Recovery, Marijuana Anonymous
Typical Treatment Structure
- 12-week IOP combining CBT + MET + CM
- Weekly to biweekly individual therapy
- Biweekly urine testing
- 12-step or peer support group attendance
Off-Label Pharmacotherapy (Limited Evidence)
- Bupropion — modest evidence for co-occurring depression + cannabis use
- Gabapentin — modest evidence for cannabis withdrawal-related anxiety and insomnia
- Nabilone — synthetic cannabinoid used in some trials (not widely adopted)
Teen and Young-Adult Cannabis Use
Cannabis use disorder rates are highest in adolescents and young adults. The clinical picture differs:
- Higher dependence risk — 17% of adolescent users develop CUD vs 9% of adult users
- Academic and occupational decline often prompts treatment entry
- Co-occurring ADHD, depression, anxiety are common
- Family therapy is a larger component of treatment
- Specialized adolescent tracks in some facilities
Adolescent cannabis treatment costs typically run 10–20% higher due to specialized programming and family involvement.
Program Length
| Duration | Best For | Insured OOP | Self-Pay |
|---|---|---|---|
| 30 days | Severe use with co-occurring conditions, CHS, unsafe environment | $4,500 – $15,000 | $11,000 – $35,000 |
| 60 days | Severe cases with multiple prior treatments | Capped at OOP max | $22,000 – $70,000 |
| IOP (12 weeks) | Most cannabis use disorder cases | $1,000 – $3,000 | $3,000 – $8,000 |
IOP is the most common level of care for cannabis use disorder. Inpatient is reserved for severe cases.
Does Insurance Cover Marijuana Rehab?
Yes — ACA + MHPAEA + 2024 final rule. See does insurance cover rehab.
Carrier pages: Aetna · Cigna · UnitedHealthcare · BCBS · Humana · Kaiser · Molina
Pre-Admission Questions
- Is the facility’s IOP CBT-certified with CM component?
- Is there family therapy for adolescent/young adult patients?
- Is CHS-specific medical evaluation available if relevant?
- Is dual diagnosis treatment available for co-occurring depression/anxiety?
- What’s my OOP max, and what’s met year-to-date?
If You Don’t Have Insurance
See rehab cost without insurance. Many cannabis-specific IOP programs are available at $100–$300/session self-pay or sliding-scale.
Sources
- National Institute on Drug Abuse. “Cannabis (Marijuana) Research Report.” 2024. https://nida.nih.gov/publications/research-reports/marijuana
- Substance Abuse and Mental Health Services Administration. “National Survey on Drug Use and Health.” 2024. https://www.samhsa.gov/data/
- American Psychiatric Association. “DSM-5 Cannabis Use Disorder Criteria.” 2024.
- Centers for Disease Control and Prevention. “Cannabis and Public Health.” 2024. https://www.cdc.gov/marijuana/
- Rubio-Tapia A, et al. “Cannabinoid Hyperemesis Syndrome.” American Journal of Gastroenterology. Updated reviews.
- National Academies of Sciences, Engineering, and Medicine. “The Health Effects of Cannabis and Cannabinoids.” 2017.
- U.S. Department of Labor. “Mental Health Parity and Addiction Equity Act Final Rule (September 2024).” https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/mental-health-and-substance-use-disorder-parity
Your Plan May Not Cover Marijuana Treatment.
Even with insurance, many people discover their plan doesn't cover residential treatment at the level they need. A broker who specializes in behavioral health coverage can review your situation and find a plan that works.
Call 1-866-454-9577Free Consultation · No Obligation
Prodest Insurance Group is a licensed, independent health insurance brokerage. Calling the number above connects you with a licensed insurance agent, not a treatment facility. Insurance placement is a separate service from treatment referral.
Frequently Asked Questions
How much does a marijuana addiction cost?
Cannabis use disorder costs vary by use pattern and product. A daily heavy user at current dispensary or street prices spends $3,000–$15,000 per year on product ($8–$40/day). Add productivity losses ($5,000–$25,000 for impaired work performance), transportation impairment (DUI legal costs average $10,000–$25,000 if convicted), and cannabis-related ER visits ($1,500–$4,500 each — increasingly common with high-THC concentrates and Cannabinoid Hyperemesis Syndrome). Total untreated cost for a moderate-to-severe cannabis use disorder typically runs $15,000–$75,000+ per year. A 30-day inpatient program at $4,500–$15,000 insured cost is usually less than one year of untreated use plus associated costs.
Should you go to rehab for marijuana?
Rehab is warranted when you meet criteria for cannabis use disorder and have tried unsuccessfully to quit. Clinical criteria (DSM-5) include: using more than intended, unsuccessful attempts to cut down, spending significant time obtaining/using/recovering, cravings, use despite negative consequences, tolerance, and withdrawal. Other indicators of benefit: daily use of high-THC concentrates (80–99% THC), history of Cannabinoid Hyperemesis Syndrome (CHS), co-occurring depression or anxiety being worsened by use, adolescent/young adult use with academic or occupational decline, legal consequences. Most cannabis use disorder is treated outpatient (IOP with CBT + contingency management). Inpatient is reserved for severe cases with co-occurring conditions or unsafe living environment.
How much is 28 days of marijuana rehab?
A 28-day inpatient cannabis rehab stay — the standard insurance billing cycle — costs $10,000 to $33,000 without insurance and $4,000 to $14,000 out-of-pocket with PPO insurance. Cannabis rehab is typically the lowest-cost rehab of any substance because there's no medically dangerous withdrawal requiring intensive detox, no MAT medication costs (no FDA-approved medications for cannabis use disorder), and most patients are appropriate for outpatient rather than inpatient care. When inpatient is used, it's often for co-occurring psychiatric conditions or unsafe living environment rather than for cannabis alone.
Do you have to pay for marijuana rehab?
Rarely at full sticker price. Under ACA and MHPAEA, insurance must cover cannabis use disorder treatment as an essential health benefit. PPO plans pay 60–80% after deductible, capped at your 2026 out-of-pocket maximum of $7,000–$9,500. Medicaid plans cover at $0–$100 copay. Uninsured patients can access sliding-scale fees, scholarship funds, single-case agreements, medical loans, and payment plans. State-funded treatment exists for patients without insurance. Because cannabis treatment is generally lower-intensity than other substances, many patients complete full evidence-based outpatient protocols for under $1,000 out-of-pocket with insurance.
How long does marijuana withdrawal last?
Cannabis withdrawal typically lasts 1–2 weeks, with peak symptoms on days 2–6. Symptoms include irritability, anxiety, insomnia, decreased appetite, restlessness, cravings, and occasional sweating. Withdrawal is not medically dangerous, but it can be uncomfortable enough to cause early treatment dropout without support. Long-term heavy users (especially high-THC concentrates or daily use since adolescence) may experience protracted symptoms — sleep disruption, mood changes, subtle cognitive effects — for 1–3 months. Sleep returns to normal more slowly than other symptoms. Exercise, sleep hygiene, and short-term non-addictive sleep aids (melatonin, trazodone, hydroxyzine) help the acute phase.
Does insurance cover marijuana rehab?
Yes. Under ACA and MHPAEA, every marketplace plan and most employer plans cover cannabis use disorder treatment as an essential health benefit. Coverage includes medical stabilization if needed, residential inpatient, PHP, IOP, standard outpatient, CBT, motivational enhancement therapy, and contingency management. PPO plans pay 60–80% after deductible, capped at OOP max. Medicaid covers at $0–$100. Historically, some insurers pushed back on cannabis-specific claims (arguing it wasn't 'medically necessary' given lack of dangerous withdrawal), but the 2024 MHPAEA final rule prohibits this kind of disparate treatment vs comparable substance use disorders.
What is Cannabinoid Hyperemesis Syndrome (CHS)?
CHS is a condition marked by recurring episodes of severe nausea, vomiting, and abdominal pain in heavy, long-term cannabis users. It's been increasingly diagnosed since 2010, accelerating dramatically with high-THC concentrates. Symptoms are paradoxically relieved by hot showers or baths. ER visits for acute CHS episodes cost $1,500–$4,500 each; recurrent episodes commonly result in multiple ED visits before diagnosis. Treatment: complete cessation of cannabis is the only reliable cure; symptoms resolve in 1–3 weeks after cessation. Topical capsaicin, haloperidol, and IV fluids manage acute episodes. Insurance covers CHS treatment under medical, not SUD, benefit.
Is marijuana addictive?
Yes. Approximately 9% of people who use cannabis develop cannabis use disorder, rising to 17% for those who start in adolescence, and over 25% for daily users. NIDA estimates 4 million Americans meet diagnostic criteria for cannabis use disorder. Current-generation products (15–30% THC flower, 80–99% THC concentrates like wax, shatter, live resin, and rosin) produce dependence and withdrawal at much higher rates than older, lower-THC products. Delta-8, delta-9, and delta-10 THC products sold in some states under loopholes in the 2018 Farm Bill produce similar dependence risks despite less FDA oversight.